{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:11:16Z","timestamp":1785337876769,"version":"3.55.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T00:00:00Z","timestamp":1711843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T00:00:00Z","timestamp":1711843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40290-024-00521-2","type":"journal-article","created":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T13:01:36Z","timestamp":1711890096000},"page":"217-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Sponsor\u2019s Perspective on the Contribution of Regulatory-Required Observational Post-Marketing Studies to Understanding Human Drug Product Benefit\/Risk in Japan"],"prefix":"10.1007","volume":"38","author":[{"given":"Kevin D.","family":"Wolter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asayuki","family":"Kamatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Imaeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi","family":"Dagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Safferman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5547-1801","authenticated-orcid":false,"given":"Rod","family":"Junor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,31]]},"reference":[{"key":"521_CR1","unstructured":"FDA post-marketing requirements and commitments: introduction. US Food and Drug Administration https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/postmarket-requirements-and-commitments. Accessed 14 Feb 2024."},{"key":"521_CR2","unstructured":"Pediatric Research Equity Act. US Food and Drug Administration https:\/\/www.fda.gov\/drugs\/development-resources\/pediatric-research-equity-act-prea. Accessed 14 Feb 2024."},{"key":"521_CR3","unstructured":"Human regulatory: post-authorisation safety studies. European Medicines Agency https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/pharmacovigilance-post-authorisation\/post-authorisation-safety-studies-pass. Accessed 14 Feb 2024."},{"key":"521_CR4","unstructured":"Human regulatory: post-authorisation efficacy studies. European Medicines Agency https:\/\/www.ema.europa.eu\/en\/pharmacovigilance-post-authorisation\/post-authorisation-efficacy-studies-questions-and-answers. Accessed 14 Feb 2024."},{"issue":"6","key":"521_CR5","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/cpt.2335","volume":"111","author":"L McKinley","year":"2022","unstructured":"McKinley L, Pressler ML, Hiatt MA, Gregory W. A sponsor\u2019s view on postmarketing regulatory commitments involving human drug products. Clin Pharmacol Ther. 2022 Jun;111(6):1199\u2013201.","journal-title":"Clin Pharmacol Ther"},{"key":"521_CR6","first-page":"157","volume":"29","author":"TW Meade","year":"1975","unstructured":"Meade TW. Subacute myelo-optic neuropathy and clioquinol. An epidemiological case-history for diagnosis. Br J Preventive Soc Med. 1975;29:157\u201369.","journal-title":"Br J Preventive Soc Med"},{"key":"521_CR7","unstructured":"International Conference on Harmonisation ff Technical Requirements for Registration of Pharmaceuticals for Human Use. Structure And Content of Clinical Study Reports E3. Current Step 4 version dated 30 November 1995. https:\/\/database.ich.org\/sites\/default\/files\/E3_Guideline.pdf. Accessed 14 Feb 2024."},{"key":"521_CR8","unstructured":"Procedures for Developing Post-marketing Study Plan. January 23, 2018. Pharmaceuticals and Medical Devices Agency https:\/\/www.pmda.go.jp\/files\/000226080.pdf. Accessed 27 Feb 2024."},{"key":"521_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40290-014-0046-6","volume":"28","author":"K Kanmuri","year":"2014","unstructured":"Kanmuri K, Narukawa M. Characteristics of post-marketing studies and their contribution to post-marketing safety measures in Japan. Pharm Med. 2014;28:67\u201373.","journal-title":"Pharm Med"},{"key":"521_CR10","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/pds.4879","volume":"10","author":"M Yamaguchi","year":"2019","unstructured":"Yamaguchi M, Inomata S, Harada S, Matsuzaki Y, Kawaguchi M, Ujibe M, Kishiba M, Fujimura Y, Kimura M, Murata K, Nakashima N, Nakayama M, Ohe K, Orii T, Sueoka E, Suzuki T, Yokoi H, Takahashi F, Uyama Y. Establishment of the MID-NET medical information database network as a reliable and valuable database for drug safety assessments in Japan. Pharmacoepidemiol Drug Saf. 2019;10:1395\u2013404.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"521_CR11","unstructured":"About MDV database. Medical Data Vision https:\/\/en.mdv.co.jp\/about-mdv-database\/. Accessed 5 Mar 2024."}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-024-00521-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-024-00521-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-024-00521-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T19:10:41Z","timestamp":1715973041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-024-00521-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,31]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1007\/s40290-024-00521-2","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,31]]},"assertion":[{"value":"5 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are employees of Pfizer and hold stock in Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"PMDA reexamination reports .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"K.W. and A.K. were responsible for the acquisition, analysis, and interpretation of data. K.W. and R.J. drafted the manuscript. All authors made substantial contributions to the design of the research, revised it critically for important intellectual content, approved the version to be published, and are accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}